Phase I Study With Sorafenib in Combination With Carboplatin and Paclitaxel to Evaluate the Safety and Pharmacokinetics of This Combination in Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2014
At a glance
- Drugs Sorafenib (Primary) ; Carboplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 18 Sep 2009 Actual end date (1 Feb 2009) added as reported by ClinicalTrials.gov.
- 18 Sep 2009 Actual patient number (19) added as reported by ClinicalTrials.gov.
- 18 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.